Xiao-hui ZHANG, Jin-zhe PAN, Ning WU, Shu TANG, Xiang-dong LEI, Yang-yang SUN, Joerg HARTUNG, En-dong BAO

Investigation of the efficiency and safety of tilmicosin phosphate in treating experimental mycoplasmal infections in pigs

In order to evaluate the in vivo therapeutic effect of oral administration of tilmicosin phosphate on mycoplasmal pneumonia in swine and its safety for the infected swine, the model of mycoplasmal pneumonia disease in swine was established by artificial infection, and indices such as efficiency, cure rate, death rate, the score of lung lesion, and the routine blood tests, blood biochemistry, and routine urine tests of tested swine were determined. The results showed that all of the dosage groups of 100 mg/L, 80 mg/L, 60 mg/L of 10% tilmicosin phosphate soluble powder demonstrated distinct therapeutic effects on mycoplasmal pneumonia in pigs, significantly reducing the scores of lung lesions in diseased pigs, and that the treatment effect of 60-80 mg/L tilmicosin phosphate soluble powder was equivalent to that of 10% tilmicosin soluble powder. Administration of 10% tilmicosin phosphate soluble powder improved the weight gain of the diseased swine. Treatment of infected pigs with 60?100 mg/L of 10% tilmicosin phosphate soluble powder did not seem to influence the routine blood tests, biochemical index, and routine urine tests, and is therefore safe for diseased swine. In conclusion, administration of 10% tilmicosin phosphate soluble powder is effective and safe to treat artificially infected swine with mycoplasmal pneumonia.

Keywords:

Tilmicosin phosphate, treatment effect, safety, mycoplasmal pneumonia, pigs,

PDF

___

Holst S, Yeske P, Pieters M. Elimination of Mycoplasma hyopneumoniae from breed-to-wean farms: a review of current protocols with emphasis on herd closure and medication. J Swine Health Prod 2015; 23: 321-330.
Blanchard B, Vena M, Cavalier A, Le Lannic J, Gouranton J, Kobisch M. Electron microscopic observation of the respiratory tract of SPF piglets inoculated with Mycoplasma hyopneumoniae . Vet Microbiol 1992; 30: 329-341.
Sibila M, Pieters M, Molitor T, Maes D, Haesebrouck F, Segales J. Current perspectives on the diagnosis and epidemiology of Mycoplasma hyopneumoniae infection. Vet J 2009; 181: 221- 231.
Garcia-Morante B, Segales J, Fraile L, Perez de Rozas A, Maiti H, Coll T, Sibila M. Assessment of Mycoplasma hyopneumoniae induced pneumonia using different lung lesion scoring systems: a comparative review. J Comp Pathol 2015; 154: 125-134.
Michiels A, Piepers S, Ulens T, Van Ransbeeck N, Del Pozo Sacristan R, Sierens A,Maes D. Impact of particulate matter and ammonia on average daily weight gain, mortality and lung lesions in pigs. Prev Vet Med 2015; 121: 99-107.
Dubosson C, Conzelmann C, Miserez R, Boerlin P, Frey J, Zimmermann W, Kuhnert P. Development of two real-time PCR assays for the detection of Mycoplasma hyopneumoniae in clinical samples. Vet Microbiol 2005; 102: 55-65.
Strait E, Madsen M, Minion F, Christopher-Hennings J, Dammen M, Jones K, Thacker E. Real-time PCR assays to address genetic diversity among strains of Mycoplasma hyopneumoniae . J Clin Microbiol 2008; 46: 2491-2498.
Maes D, Sibila M, Kuhnert P, Segales J, Haesebrouck F, Pieters M. Update on Mycoplasma hyopneumoniae infections in pigs: knowledge gaps for improved disease control. Transbound Emerg Dis 2017; 23: doi: 10.1111/tbed.12677.
Zhang P, Hao H, Li J, Ahmad I, Cheng G, Chen D, Tao Y, Huang L, Wang Y, Dai M. The epidemiologic and pharmacodynamic cutoff values of tilmicosin against Haemophilus parasuis . Front Microbiol 2016; 7: 385.
Kang S, Li Z, Yin Z, Jia R, Song X, Li L, Chen Z, Peng L, Qu J, Hu Z et al. The antibacterial mechanism of berberine against Actinobacillus pleuropneumoniae . Nat Prod Res 2015; 29: 2203- 2206.
Frank GH, Briggs RE, Loan RW, Purdy CW, Zehr ES. Effects of tilmicosin treatment on Pasteurella haemolytica organisms in nasal secretion specimens of calves with respiratory tract disease. Am J Vet Res 2000; 61: 525-529.
Naccari F, Giofrè F, Pellegrino M, Calò M, Licata P, Carli S. Effectiveness and kinetic behaviour of tilmicosin in the treatment of respiratory infections in sheep. Vet Rec 2001; 148: 773-776.
Zhang L, Zhao L, Liu Y, Liu J, Li X. Pharmacokinetics of tilmicosin in healthy pigs and in pigs experimentally infected with Haemophilus parasuis . J Vet Sci 2017; 18: 431-437.
Tavio M, Poveda C, Assuncao P, Ramirez A, Poveda J. In vitro activity of tylvalosin against Spanish field strains of Mycoplasma hyopneumoniae . Vet Rec 2014; 175: 539.
Fittipaldi N, Klopfenstein C, Gottschalk M, Broes A, Paradis MA, Dick CP. Assessment of the efficacy of tilmicosin phosphate to eliminate Actinobaclillus pleuropneumoniae from carrier pigs. Can J Vet Res 2005; 69: 146-150.
Lindecrona RH, Friis C, Nielsen JP. Pharmacokinetics and penetration of danofloxacin into the gastrointestinal tract in healthy and in Salmonella typhimurium infected pigs. Res Vet Sci 2000; 68: 211-216.
Sang K, Hao H, Huang L, Wang X, Yuan Z. Pharmacokinetic– pharmacodynamic modeling of enrofloxacin against Escherichia coli in broilers. Front Vet Sci 2015; 2: 80.
van Miert A. Influence of febrile disease on the pharmacokinetics of veterinary drugs. Annal Vet Res 1990; 21: 11S-28S.
Shao GQ, Liu MJ, Sun PY, Wang JC, Du G, Zhou Y, Liu D. The establishment of an experimental swine model of swine mycoplasma pneumonia. Journal of Microbes and Infection 2007; 2: 215-218.
Otake S, Dee S, Corzo C, Oliveira S, Deen J. Long-distance airborne transport of infectious PRRSV and Mycoplasma hyopneumoniae from a swine population infected with multiple viral variants. Vet Microbiol 2010; 145: 198-208.
Kick AR, Tompkins MB, Hammer JM, Routh PA, Almond GW. Evaluation of peripheral lymphocytes after weaning and vaccination for Mycoplasma hyopneumoniae . Res Vet Sci 2011; 91: 68-72.
Del Pozo Sacristan R. Treatment and control of Mycoplasma hyopneumoniae infections. PhD, Ghent University, Ghent, Belgium 2014; 189.
Scorneaux B, Shryock TR. Intracellular accumulation, subcellular distribution and efflux of tilmicosin in swine phagocytes. J Vet Pharmacol Ther 1998; 21: 257268.
Paradis MA, Vessie GH, Merrill JK, Dick CP, Moore C, Charbonneau G, Gottschalk M, MacInnes JI, Higgins R, Mittal KR, Girard C, Aramini JJ, Wilson JB. Efficacy of tilmicosin in the control of experimentally induced Actinobacillus pleuropneumoniae infection in swine. Can J Vet Res 2004; 68: 7-11.
Moore GM, Mowrey DH, Tonkinson LV, Lechtenberg KF, Schneider JH. Efficacy dose determination study of tilmicosin phosphate in feed for control of pneumonia caused by Actinobacillus pleuropneumoniae in swine. Am J Vet Res 1996; 57: 220-223.
Khan AT, Zafar F. Hematological study in response of varying doses of estrogen in broiler chicken. Int J Poultry Sci 2005; 10: 748-751.
Scorneaux B, Shryock TR. Intracellular accumulation, subcellular distribution, and efflux of tilmicosin in bovine mammary, blood, and lung cells. J Dairy Sci 1999; 82: 1202- 1212.
Smith CM, Reynard AM. Textbook of Pharmacology. London: W. B. Saunders, 1992.
Elsayed M, Elkomy A, Aboubakr M, Morad M. Tissue residues, hematological and biochemical effects of tilmicosin in broiler chicken. Vet Med Int 2014; doi: 10.1155/2014/502872.
Shiwa T, Nishimura M, Kato M. The effectiveness of the semi- quantitative assessment of microalbuminuria using routine urine dipstick screening in patients with diabetes. Intern Med 2018; 57: 503-506.